{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.04","upperLimit":"53.81","value":"23.08"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"23.16","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"14"}],"units":"Participants"}],"description":"Improvement in glucose control was defined as a participant who experiences at least a 25% decrease from baseline in area under the concentration-time curve for blood glucose (AUCglucose) who has not taken an additional diabetes medication during the treatment period or increased the dosage of a concurrent diabetes medication.","dispersionType":"95% Confidence Interval","groups":[{"description":"100 mg/day for 4 weeks in Period 1, then 150 mg/day for 4 weeks in Period 2, then 200 mg/day for 4 weeks in Period 3. Period 3 was followed by a 4-week follow-up period.","id":"OG000","title":"Group 1: Low-dose Group"},{"description":"250 mg/day for 4 weeks in Period 1, then 300 mg/day for 4 weeks in Period 2, then 350 mg/day for 4 weeks in Period 3, then 400 mg/day for 4 weeks in Period 4. Period 4 was followed by a 4-week follow-up period.","id":"OG001","title":"Group 2: High-dose Group"}],"paramType":"NUMBER","populationDescription":"All enrolled participants with IGT / T2DM at Baseline who received at least one dose of study drug and had at least one post-baseline assessment.","reportingStatus":"POSTED","timeFrame":"Before and 0.5, 1, 1.5, and 2 hours after a glucose drink at Week 12 or last observation (Group 1) or Week 16 or last observation (Group 2)","title":"Percentage of Participants With IGT / T2DM Who Experienced a ≥25% Reduction in AUCglucose Following Treatment With CORT125134","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}